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Abstract
Background: Our objective was to assess whether modifications to a customized targeted RNA sequencing (RNAseq)
assay to include unique molecular identifiers (UMIs) that collapse read counts to their source mRNA counts would
improve quantification of transcripts from formalin-fixed paraffin-embedded (FFPE) tumor tissue samples. The assay
(SET4) includes signatures that measure hormone receptor and PI3-kinase related transcriptional activity (SETER/PR and
PI3Kges), and measures expression of selected activating point mutations and key breast cancer genes.
Methods: Modifications included steps to introduce eight nucleotides-long UMIs during reverse transcription (RT) in
bulk solution, followed by polymerase chain reaction (PCR) of labeled cDNA in droplets, with optimization of the
polymerase enzyme and reaction conditions. We used Lin’s concordance correlation coefficient (CCC) to measure
concordance, including precision (Rho) and accuracy (Bias), and nonparametric tests (Wilcoxon, Levene’s) to compare
the modified (NEW) SET4 assay to the original (OLD) SET4 assay and to whole transcriptome RNAseq using RNA from
matched fresh frozen (FF) and FFPE samples from 12 primary breast cancers.
Results: The modified (NEW) SET4 assay measured single transcripts (p< 0.001) and SETER/PR (p=0.002) more reproducibly
in technical replicates from FFPE samples. The modified SET4 assay was more precise for measuring single transcripts (Rho
0.966 vs 0.888, p< 0.01) but not multigene expression signatures SETER/PR (Rho 0.985 vs 0.968) or PI3Kges (Rho 0.985 vs
0.946) in FFPE, compared to FF samples. It was also more precise than wtRNAseq of FFPE for measuring transcripts (Rho
0.986 vs 0.934, p< 0.001) and SETER/PR (Rho 0.993 vs 0.915, p=0.004), but not PI3Kges (Rho 0.988 vs 0.945, p=0.051).
Accuracy (Bias) was comparable between protocols. Two samples carried a PIK3CA mutation, and measurements of
transcribed mutant allele fraction was similar in FF and FFPE samples and appeared more precise with the modified SET4
assay. Amplification efficiency (reads per UMI) was consistent in FF and FFPE samples, and close to the theoretically
expected value, when the library size exceeded 400,000 aligned reads.
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Conclusions: Modifications to the targeted RNAseq protocol for SET4 assay significantly increased the precision of UMI-
based and reads-based measurements of individual transcripts, multi-gene signatures, and mutant transcript fraction,
particularly with FFPE samples.
Keywords: Targeted RNAseq, Unique molecular identifiers, Assay development, Breast cancer
Background
Although most gene expression signatures are currently
based on RT-PCR amplification or direct hybridization
to oligonucleotide probes [1], targeted RNA sequencing
(RNAseq) is developing into an alternative technology
for translational research and clinical testing [2, 3]. Pre-
viously, we demonstrated that the quality of gene expres-
sion quantification by whole transcriptome or targeted
RNAseq measurement did not differ significantly when
using three different methods (kits) to purify RNA from
formalin-fixed paraffin-embedded (FFPE) samples [4, 5].
Such promising analytical performance compels devel-
opment of evidence-based standard operating proce-
dures for clinical-level implementation of RNAseq on
routine FFPE samples. It also raises the possibility of
whether the introduction of unique molecular identifiers
(UMIs), also known as molecular barcodes, during re-
verse transcription could help reduce the inherent vari-
ability in amplification of target RNA sequences from
FFPE tissue samples by enabling more precise enumer-
ation of sequencing reads according to the source
mRNA molecules instead of the total read counts. Thus,
we modified our previously published targeted RNAseq
assay that is intended to predict sensitivity to endocrine-
based treatments from breast cancer samples, in order
to evaluate this potential improvement in transcript
quantification [5, 6].
Endocrine-based therapies have a principal role in the
treatment of primary and metastatic breast cancer that
is estrogen receptor-positive and HER2-negative. As
endocrine resistance can be acquired there is also a need
to predict sensitivity to treatment during the course of
Stage IV disease to potentially direct patients to alterna-
tive treatment approaches if available. We have reported
that patients stratified as endocrine sensitive based on
the targeted RNAseq assay for SETER/PR index (of hor-
mone receptor-related transcription) had longer survival
when they received endocrine therapy as their next
treatment, and that was independent from clinical-
pathologic risk factors or detection of activating muta-
tion in the ESR1 gene [6]. Activating PIK3CA mutations
are also associated with greater benefit from PIK3CA in-
hibitor alpelisib [7], and with letrozole compared with
tamoxifen as endocrine therapy [8]. Hence, we included
a 10-gene transcriptional signature (PI3Kges) of Sinn
et al that was curated from the published 287-gene
microarray-based signature of transcription related to
PI3K activation due to activating mutations in PIK3CA
[9]. The SET4 targeted RNAseq assay also measures the
expression of two multi-gene signatures (SETER/PR index
and PI3Kges), single genes (ESR1, PGR, ERBB2, AURKA,
FGFR1) and the proportion of transcripts carrying
known hotspot mutations in ESR1 (ligand-binding do-
main), PIK3CA (helical and loop domains), AKT1 (pleck-
strin homology domain), PTEN (phosphatase tensin-type
domain), and ERBB2 (protein kinase domain). Essen-
tially, SET4 assay combines measurements of the geno-
type and phenotype related to clinically relevant
oncogenic pathways in hormone receptor-positive breast
cancer (Supplementary Table 1).
Targeted RNA sequencing (targeted RNAseq) of RNA
transcripts of interest provides increased sensitivity, dy-
namic range, reduced cost, and increased throughput
compared to standard sequencing of the whole tran-
scriptome (wtRNAseq) [10]. Although the method is
compatible with RNA derived from either FF or FFPE
tissue samples [11] and shows good concordance be-
tween sample types, we had observed a linear bias with
higher SETER/PR index measured from wtRNAseq, com-
pared to the targeted RNAseq SET4 assay [5]. In this
study, we updated our methods for performing the SET4
assay, including introduction of UMIs, and demonstrate
the resultant increase in technical reproducibility, ro-
bustness to preanalytical and analytical conditions, and
reduction of inter-platform bias between targeted and
wtRNAseq.
Methods
RNA extraction from tissue samples
We used residual RNA from the same samples as previ-
ously reported [5]. Briefly, those were surgically resected
tissue samples collected from 12 treatment-naïve, stage
I-III invasive breast cancers (IRB protocol LAB08–0824),
homogenized [12], and split for processing into fresh
frozen (FF) and FFPE conditions [5]. RNA was extracted
from thawed FF samples using RNeasy Mini Kit (Qiagen,
Hilden, Germany) [4, 12]. RNA was extracted from adja-
cent FFPE tissue-block sections using FFPE RNA purifi-
cation Kit (Norgen, Thorold, Canada), which we had
shown to be comparable to two other commercial kits
[5]. Two replicate RNA extractions for each sample were
performed in parallel for both FF and FFPE. Both the FF
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and FFPE RNA isolation protocols used DNase I treat-
ment. RNA concentration was quantified by Nanodrop
(Nanodrop Technologies, Wilmington, DE). An add-
itional ethanol precipitation step was applied to further
clean RNA with A260/230 below 1.0.
RNA sequencing
RNA samples underwent wtRNAseq and targeted RNA-
seq for 18 SETER/PR index transcripts, 10 PI3Kges tran-
scripts, 6 well-known breast cancer mutation hotspots
(in ESR1, PIK3CA, AKT1, PTEN, and ERBB2), 10 control
transcripts, and transcripts for FGFR1, AURKA, PGR,
and ERBB2 (Supplementary Table 1). The transcript of
one gene, NAT1, is shared between the SETER/PR index
and PI3Kges. For each of the 12 breast cancer tissue
samples, two technical replicates were performed for
both FF and FFPE RNA, using the wtRNAseq and the
two targeted RNAseq protocols (OLD and NEW). We
performed at least six replicates from the two tumors
with mutation detected, to further examine the mutation
detection reproducibility.
wtRNAseq libraries were prepared using the RNA
HyperPrep kit with RiboErase (HMR) (Kapa Biosystems,
Wilmington, MA), as previously described [4]. Sequencing
was performed using Illumina HiSeq 4000 (Illumina, San
Diego, CA), with 6 libraries pooled per lane including FF
and FFPE samples.
Targeted RNAseq libraries were prepared using a set
of custom multiplex primers including an approximately
20-nucleotide (20-nt) gene specific sequence and either
a 17-nt Illumina adaptor (5′-CGCTCTTCCGATCT
CTG-3′) on the 5′-end of the forward primer or a 17-nt
Illumina adaptor (5′-TGCTCTTCC-GATCTGAC-3′)
on the 5′-end of the reverse primer.
The original reads-based targeted RNAseq sequencing
libraries without UMIs (OLD_reads) were prepared
using a one-step RT-PCR protocol as described previ-
ously [5]. Purified RNA was mixed with a pool of cus-
tom primer pairs, droplet stabilizer (BioRad, Hercules,
CA), and SuperScript III reagents (ThermoFisher Scien-
tific, Waltham, MA) to prepare a reaction master mix.
Droplet-generation was performed using RainDance
Source system and followed by a one-step RT-PCR reac-
tion (RT at 55 °C for 30 min, then 1st PCR with 55 amp-
lification cycles) carried out within the droplets. The
droplets were destabilized and the released PCR prod-
ucts were purified using SPRIselect magnetic bead
(Beckman Coulter, Brea, CA). A 10-cycle 2nd PCR was
performed using PlatinumTaq High Fidelity DNA Poly-
merase (ThermoFisher Scientific, Waltham, MA) to in-
corporate RainDance DirectSeq primers for sample
indexing and Illumina specific adapters for cluster gener-
ation/sequencing. After bead purification and Bioanaly-
zer quantification, the indexed libraries were pooled and
sequenced on the Illumina Miseq platform (Illumina,
San Diego, CA) with paired-end 215 bp reads using v3
chemistry reagents.
The UMI-based targeted RNAseq sequencing libraries
(NEW_UMIs) were prepared by making the following
adjustments to the ‘OLD_reads’ protocol described
above. Purified RNA was reverse-transcribed at 55 °C for
10 min using SuperScript IV (ThermoFisher Scientific,
Waltham, MA) and 8-nt UMI-containing primers de-
signed as follows: 5′-Illumina adaptor sequence-NNNN
NNNN-reverse primer sequence-3′, and synthesized by
Integrated DNA Technologies, San Diego, CA. The re-
sultant cDNA was purified using SPRIselect beads to re-
move excess primers. The cDNA, gene-specific forward
primers, a universal reverse primer (5′-TGCTCTTCC-
GATCTGAC-3′), and droplet stabilizer, were added to
TaqMan Genotyping Master Mix (ThermoFisher Scien-
tific, Waltham, MA), and droplets were generated using
the RainDance Source system. Then a 40-cycle droplet
PCR (1st PCR) was carried out to amplify the cDNA.
After that, purification, 2nd PCR, library quantification
and sequencing were performed as described above, with
the following addition: pooled libraries were treated with
Illumina Free Adaptor Blocking reagent prior to sequen-
cing to minimize potential index hopping levels and to
enhance data quality.
Pre-processing of sequencing reads, alignment and
quantification
Processing of wtRNAseq reads was performed as previ-
ously described [5]. Two custom pipelines were devel-
oped to perform read-based and UMI-based analyses of
the targeted RNAseq data. For read-based analysis,
blastn was used to map the paired-end reads to a custom
cDNA reference including only the targeted genes [13].
The mapping results were processed by in-house Perl
scripts. Reads with matched region shorter than 90 nt
(the insert size is between 150 and 200 bp) or identity
percentage less than 80% were filtered out. Transcript
levels were quantified by counting the total number of
aligned reads on each target. SETER/PR and PI3Kges were
calculated as described before [4]. A single nucleotide
mutation was reported if sequencing depth at a genomic
position was greater than 100, the allele frequency (AF)
was greater than 5%, and the ratio of R1 and R2 reads
was between 0.8 and 1.2.
For UMI-based analysis, after reads were aligned and
filtered as described above, the nucleotides between the
9th and 25th (gene specific reverse primer sequence)
from the reverse read (R2) were extracted to identify
each target gene. The first 8 nucleotides were extracted
from the R2 reads as a unique molecular identifier
(UMI). Reads with unmatched nucleotide within the 17-
nt gene specific sequence or irregular length of UMI
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were excluded from further analysis. Each target has cer-
tain number of UMI groups (distinct transcripts), and
each group may have one or more reads (PCR dupli-
cates). If a UMI group contained 2% or less of the reads
in the most frequent UMI group for that target, then it
was removed from further analysis. Reads in the same
UMI group were considered PCR duplicates and one
read was randomly selected as the representative se-
quence for each UMI. Then the corresponding forward
reads (R1) were pulled out based on the name of R2
reads. This small set of reads, corresponding to filtered
unique reverse-transcribe-able mRNA species in the
sample, was used for downstream analyses instead of
total reads. Transcript level quantification and mutation
analyses were processed as described above in the read-
based analysis. An additional criterion was required for
the mutation calls: sequencing depth at a position had to
be at least 10 unique UMIs, roughly equivalent to 80–
100 reads.
Statistical analysis
Pearson correlation coefficient (r) was used to compare
gene expression levels and transcriptional signature
scores between FF and FFPE samples, and between
wtRNAseq and targeted RNAseq assays. Measurements
from technical replicates were averaged prior to analyses.
Agreement was also assessed using Lin’s concordance
correlation coefficient (CCC) [14]. Lin’s coefficient
modifies the Pearson correlation coefficient by assessing
not only how precisely scattered data approximate the
line of best fit (Correlation term ranging from − 1 to 1;
higher is better) but also accuracy, measured as how far
that line is from perfect agreement (Bias term ranging
from 0 to 1; higher is better). Nemenyi’s test of multiple
comparisons was used to compare reproducibility be-
tween protocols. Nonparametric Wilcoxon one-sample
test and Mann-Whitney U-test were used to compare
average of obtained results (e.g. CCC value) for individ-
ual gene measurements between protocols. Levene’s test
was used to compare variances of obtained results (e.g.
CCC value) for individual gene measurements between
protocols. Significance level was set to 0.05 in all
analyses.
Results
Reproducibility of gene expression measurements
The median absolute difference of expression measure-
ments (using total read counts) between technical repli-
cate assays using RNA extracted from FFPE was
significantly lower using the ‘NEW’ UMI-based protocol
than with the original protocol (NEW_reads vs OLD_
reads, p-value < 0.001) for individual transcripts (Fig. 1a
and Supplementary Table 2) and both multi-gene signa-
tures (Fig. 1b and Supplementary Table 2). A similar
result was observed when comparing protocols with
RNA from FF samples (Supplementary Fig. 1 and Sup-
plementary Table 2), but the absolute difference was less
due to less variable measurements from FF RNA [5].
Collapsing the total reads counts to UMI-based counts
(NEW_reads vs NEW_UMIs) did not change the vari-
ance for measurements of individual transcripts (p-value
= 0.94) or multi-gene signatures (p-values = 0.94, 1.00)
(Supplementary Table 2). This suggests that the adjust-
ments incorporated into the NEW_reads protocol re-
moved most of the bias introduced by the PCR steps
without requiring the use of UMIs. Raw read depth for
individual genes was similar between protocols and was
more reproducible between technical replicates using
the NEW_UMIs protocol in both FF (Supplementary
Fig. 2) and FFPE samples (Supplementary Fig. 3).
Distribution of UMIs
We compared the percentage of all possible UMI se-
quences (65,536 different UMIs for 8 nt sequences) that
were observed in a single library (sequencing saturation)
against the total number of aligned reads (library size),
for targeted RNAseq libraries from both FF and FFPE
samples (Fig. 2a). For comparison, we included idealized
theoretical sequencing saturation curves based on the
negative binomial distribution that assumes no bias from
PCR or other factors, e.g. sequencing errors in UMIs
(dashed lines). There was only a very small difference
observed (< 5%) between the ideal and fitted distribu-
tions for libraries larger than 400,000 aligned reads.
The negative binomial distribution is a suitable model
for sequencing read distributions because the modelled
variance captures between-sample variance [15]. Our ob-
served distributions of UMIs were well represented using
negative binomial distribution, suggesting that measured
reads were relatively free from additional introduced bias
or noise. We observed that the average number of reads
per UMI was close to the theoretical expected value
(dashed line) for libraries larger than 400,000 aligned
reads (Fig. 2b). The overlap of FF and FFPE distributions
seen suggests that the NEW protocol had negligible add-
itional PCR bias from cross-linking of RNA in FFPE
samples (Fig. 2b).
Concordance between sample types and platforms
The concordance of individual transcript measurements
between matched FF and FFPE samples was greater with
the NEW_UMIs protocol, exhibiting significantly higher
Rho (median 0.966 vs 0.888 for NEW_UMI vs OLD pro-
tocols; p-value < 0.001) but similar bias (median 0.958 vs
0.907 for NEW_UMI vs OLD protocols; p-value = 0.53)
(Fig. 3a and Supplementary Table 3). Both multi-gene
signatures were strongly concordant between matched
FF and FFPE samples, SETER/PR (CCC 0.901, 95%CI
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Fig. 1 Technical variance of expression measurements from targeted RNAseq data on FFPE samples. a Distribution of absolute difference in
expression level between replicates for 28 targeted genes within each protocol. b Distribution of absolute difference in molecular signature score
between replicates for two signatures within each protocol. Panel B shows boxplots, rather than violin plots, due to smaller sample size in that
analysis (n=12 vs n=324)
Fig. 2 Sequencing saturation for gene quantification. a Percent of all possible UMIs observed in a sample (sequencing saturation) as a function of
the total number of aligned reads (library size). The black dotted line shows the theoretical sequencing saturation assuming no PCR bias or
sequencing errors in UMIs (binomial distribution). The colored dotted lines show sequencing saturation modelled by a negative binomial
distribution fitted to the observed values, separately for each sample type. One hundred percent means 65,536 unique UMIs. b Association of the
average number of reads per UMI and total number of aligned reads (library size). The black dotted line shows the theoretical relationship based
on the binomial distribution. Colored solid lines show linear regression fitted to observed values for each sample type
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0.766–0.960) and the PIK3CA-related PI3Kges (CCC
0.982, 95%CI 0.941–0.994), representing a significant
improvement over the OLD protocol for the PI3Kges
(CCC 0.861, 95%CI 0.680–0.943), but not significantly
different for SETER/PR (Table 1 and Fig. 3b). The
NEW_UMIs protocol appears to have shifted the lo-
cation of both signatures, correcting lower FFPE
scores in PI3Kges, but introducing a small location
shift bias in the SETER/PR index (Fig. 3b). Measure-
ments of both multi-gene signatures had minimal
scatter (Rho 0.985, Table 1).
There was strong concordance between targeted RNA-
seq and wtRNAseq measurements of individual tran-
scripts in both FF and FFPE samples (Supplementary
Table 4 and Supplementary Fig. 4). That correlation was
significantly improved with the NEW protocol for both
FF and FFPE samples, and included a decrease in loca-
tion bias with FFPE samples (Supplementary Table 5;
median Rho in FF 0.979 vs 0.947, median Rho in FFPE
0.986 vs 0.934 for NEW_UMI vs OLD protocols; p <
0.001 in both cases).
Quantification of transcribed mutant allele fraction
Activating mutations in PIK3CA transcripts were de-
tected in two different primary cancer samples, one con-
taining a variant (PIK3CA E545K) at high mutant allele
fraction variant and another cancer containing a differ-
ent variant (PIK3CA H1047R) at a lower allele fraction.
These results were not adjusted for histologic tumour
cell component. In both cases, we performed at least six
replicate experiments for all assay conditions. The high
variability in the estimated mutant allele fraction from
FFPE samples using the OLD_reads protocol was lower
with the NEW_reads and NEW_UMIs protocols (Fig. 4
and Supplementary Table 6). With the OLD protocol,
the mutation rates varied among technical replicates
(CV = 78 and 48%, respectively, for the two activating
PI3KCA mutations). With the NEW protocol (NEW_
reads and NEW_UMIs), the mutation rate variation was
mitigated and the CV among technical replicates was re-
duced to approximately 10% for both mutations. We
also summarize the allele fraction of the same mutations
using wtRNAseq. However, due to much lower depth of
Fig. 3 Concordance of gene expression measurements between FFPE and FF samples from the targeted RNAseq assays. a Distribution of the
components of the concordance correlation coefficient (CCC), Pearson correlation coefficient (Rho), overall bias, scale bias and location bias, for
the 28 signature genes within each protocol. b Concordance for the two transcriptional signature scores for two protocols
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coverage in the region of selected mutations on whole
transcriptome platform, the variance of allele fractions
was higher with wtRNAseq than from targeted RNAseq
using the UMI-based protocol (Fig. 4 and Supplemen-
tary Table 6). Allele frequency calls were slightly lower
from FFPE samples and were identical when calculated
from total reads counts or UMI-based counts in both FF
and FFPE samples (Fig. 4 and Supplementary Table 7).
Discussion
Amplicon-based targeted RNAseq is a highly multiplexed
PCR approach that relies on efficient and accurate cDNA
synthesis and amplification. High performance of pooled
primers, robust reverse transcriptase, and unbiased PCR
amplification are critical to the success of targeted RNA-
seq. When working with FFPE RNA, the reverse transcrip-
tion efficiency is relatively low due to RNA fragmentation
and modification that occurs during FFPE fixation. With
the original “OLD” protocol, we observed lower detection
reproducibility in FFPE RNA compared to FF, which we
assume was caused by the low efficiency and uneven sam-
pling of RT-PCR. In other words, input FFPE RNA frag-
ments were not equally reverse transcribed into cDNA, so
were not equally represented in the sequencing data. Add-
itionally, amplification bias might also affect the precision
and accuracy of RNAseq in quantifying transcript level
with FFPE tissues. Labeling individual transcripts with
UMIs makes it possible to identify and correct such biases.
To this end, we made three major adjustments to the
OLD protocol in order to improve transcript quantitation
from FFPE samples: (i) a two-step RT-PCR process re-
placed the one-step RT-PCR; (ii) SuperScript IV replaced
SuperScript III reverse transcriptase; (iii) UMIs were at-
tached to individual mRNA molecules during cDNA
synthesis.
Although the primer pairs used in this assay were de-
signed carefully and examined thoroughly, the cross
interaction among pooled primers is unavoidable and
Table 1 Concordance of the two BC signatures, and gene expression, between matched FFPE and FF samples. Gene Expression
refers to individual gene measurements, for which values in the table are medians over all genes. The combination of protocol
(NEW vs OLD) and data summarization of mapped counts (UMI groups vs reads). Bold font indicates higher value for given
signature




Rho Bias Scale Location
PIK3CA OLD_reads 0.861 0.680 0.943 0.946 0.910 0.729 0.313
NEW_reads 0.980 0.934 0.994 0.984 0.995 0.956 0.089
NEW_UMIs 0.982 0.941 0.994 0.985 0.996 0.950 0.072
SET_ERPR OLD_reads 0.956 0.871 0.985 0.968 0.987 0.881 0.103
NEW_reads 0.901 0.764 0.960 0.984 0.916 0.953 −0.425
NEW_UMIs 0.901 0.766 0.960 0.985 0.915 0.977 −0.432
Gene Expression OLD_reads 0.785 – – 0.888 0.907 0.967 0.018
NEW_reads 0.911 – – 0.977 0.951 0.997 −0.015
NEW_UMIs 0.921 – – 0.966 0.958 1.019 −0.027
Fig. 4 Expressed mutations estimated from targeted RNAseq reads. Distribution of the mutant allele fraction (AF) for two activating mutations in
PIK3CA as quantified by each protocol and sample type
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could affect the efficiency of cDNA synthesis and PCR
amplification. With the OLD one-step RT-PCR protocol,
forward and reverse gene specific primers (47 pairs)
were pooled together and used for both cDNA synthesis
and PCR amplification. With the NEW two-step RT-
PCR protocol, only gene specific reverse primers (n=47)
were used for reverse transcription, and these primers
were later removed from synthesized cDNA during puri-
fication. Then, only gene specific forward primers (n=
47) and one shared reverse primer were added into the
cDNA to fulfill PCR amplification. This adjustment
halved the size of the primer pool and improved its
working efficiency and reaction evenness by minimizing
primer cross interaction. In addition, utilizing Super-
Script IV in the NEW protocol significantly improved
RT efficiency and evenness because of its superior ro-
bustness, processivity, and cDNA yields, compared to
SuperScript III that was used in the previous protocol
[16]. Adoption of the above protocol adjustments signifi-
cantly improved transcript detection and reproducible
quantification from FFPE samples, both for individual
genes and for the transcriptional signatures, and in-
creased the correlation in transcript levels between
paired FF and FFPE samples. Most importantly, this
modified protocol demonstrated great improvement in
mutation detection in FFPE samples.
The protocol was adjusted in order to introduce UMIs
into cDNA synthesis by using UMI-labeled gene specific
reverse primers. Thus, resultant cDNA fragments are in-
dividually tagged so that each mRNA molecule that is
amplified can be tracked from the original sample
through the library preparation and sequencing process.
At the end, we can count the total number of reads or
collapse the data to count the number of unique UMIs.
This approach allows identification and correction for
possible PCR amplification bias [17]. Based on UMI-
based quantification, we learned that greater than 90%
of the library complexity has been sequenced in most
cases, for both FF and FFPE samples, and the average
number of reads per UMI was close to the expected
value. These results indicated that the NEW protocol
has been optimized properly and explained why both
gene expression and mutation detection significantly im-
proved for FFPE RNA. When the libraries were prepared
using the NEW protocol, reads-based and UMI-based
quantification were similar, suggesting lack of substantial
amplification bias during library preparation. We believe
this is largely due to utilizing Droplet PCR in the proto-
col, which provides superior specificity, coverage uni-
formity, and sensitivity relative to bulk PCR. So, efficient
RT followed by droplet-based PCR of cDNA minimized
PCR amplification bias in FFPE samples and thereby ob-
viated the need for UMIs that would have helped to ac-
count for PCR amplification bias. The FFPE samples in
this study were of reasonable quality (mean 2.9 RNA in-
tegrity number and 79.5% DV200), but it will also be im-
portant to determine whether incorporation of UMIs
may be helpful with lower quality FFPE samples.
We note that the UMI counts from one replicate from
FFPE sample 18Y were systematically lower than reads-
based counts across all genes (Supplementary Fig. 3).
This observation seems aberrant from the other replicate
from sample 18Y and from all the other FFPE samples
(Supplementary Fig. 3), and from all the FF samples
(Supplementary Fig. 2). The reason for that single aber-
rant observation is not clear but might be post-
analytical, rather than technical.
The preferred read depth varies depending on the
goals of a targeted RNA-Seq study. For diagnostic pur-
poses, higher reads depth improves accuracy and reli-
ability of detection, especially for low-expression genes
and low-frequency mutations. We note that Illumina’s
recommended read depth is 3 million reads per sample
for the TruSight RNA Pan Cancer (1385 targets, average
of 2166 reads per target) and for the TruSight RNA Fu-
sion Panel (507 targets, average of 5917 reads per target)
[18]. For our SET4 assay, we recommend at least 400,
000 reads per sample (47 targets, average of 8510 reads
per target) based on our comparison with theoretical se-
quencing saturation curves from the negative binomial
distribution (Fig. 2).
Sequencing data quality is another critical factor for
successful targeted RNAseq, and the density of clonal
clusters on a sequencer has a large impact on the data
quality. Before loading, the pooled library was further
purified to remove residual free adaptors and the loading
concentration was optimized to 10pM to ensure the
cluster density about 1000 K/mm2. As a result, all raw
data created for this study were of high quality and more
than 90% of sequencing runs had both Q30 and PF
greater than 95%. This is crucial for the accuracy of gene
expression and mutation analysis.
The targeted sequencing assay showed a slight adjust-
able bias compared to wtRNAseq, illustrating a system-
atic platform difference. These employ markedly
different molecular protocols of target amplification for
library preparation, even though the actual sequencing
platforms are quite similar. The bias may also arise from
low expressed transcripts, as most noise in the data
comes from low read counts [19]. Only deeper sequen-
cing of the transcriptome may reveal low abundance
transcripts and splice junctions [20], but in many cases,
it might be too costly unless a targeted approach is used.
Amplification biases in targeted sequencing appear to
have been adequately controlled under the NEW_UMIs
protocol.
Our study was limited to only 12 cancer samples col-
lected under a supervised research protocol and does
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not represent the full diversity of specimen handling and
fixation methods expected across pathology laboratories
or for extracting RNA and performing RNA sequencing.
Also, we could not study pre-analytical effects resulting
from prolonged storage of FFPE blocks prior to section-
ing, as a potentially important factor in retrospective
analysis of clinical trial samples.
Compared to other UMI-based RNA sequencing pro-
tocols, our method uses droplet PCR for target amplifi-
cation, instead of bulk PCR. Competition between
templates may be avoided by separating templates into
picoliter-sized droplets and improve the coverage uni-
formity of sequencing and the detection sensitivity of
low-copy or rare targets. During data analysis, our se-
quencing reads were mapped to a custom cDNA refer-
ence of 150 kilobases that only including targeted genes,
whereas other methods map reads to a whole genome (3
billion bases) or transcriptome (45 million bases). Our
custom reference improves mapping speed and elimi-
nates off-target alignment. A disadvantage of our proto-
col is the additional time required for droplet generation
(about 30 min) and the associated additional cost (about
$40USD per sample).
Conclusions
Modification of the protocol for a targeted RNAseq
assay (SET4) to incorporate UMIs significantly improved
the technical reproducibility of the assay, particularly for
assays performed with FFPE tissue samples. Sequence
saturation and average read number per UMI group
were both positively correlated with library size, and
were satisfactorily close to theoretical parameters. The
protocol modification improved the concordance, mostly
improving precision, of gene expression measurements
from FFPE and FF samples, and between targeted RNA-
seq and wtRNAseq assays. The consistency of tran-
scribed variant allele fraction calls between technical
replicates was also improved. Importantly, proper
optimization of the reverse transcription step and the
use of droplet-based PCR sufficiently controlled the ana-
lytical variability from FFPE samples, such that UMI-
based counts did not further improve the accuracy of
measurements of gene expression and transcribed muta-
tion fraction from these FFPE samples. However, incorp-
oration of UMI-based analysis allowed optimization and
provides additional quality control metrics for the SET4
assay.
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